1512-PUB: Glucose Removal Rate in Patients with APECED

Autor: ERIK R. SANDINI, SAILA LAAKSO, OUTI MAKITIE, PAIVI M. PALDANIUS

Publikováno v: Diabetes. 71

Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED or APS-1) is a rare autosomal recessive disorder and diabetes (DM) is one of its more rare manifestations. Earlier, we have showed that reduction in fractional glucose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::325ce3547decc5f4bf1bf16936ffa468
https://doi.org/10.2337/db22-1512-pub

94-LB: Long-Term Clinical Benefits of Early Combination Approach in Latin American Subpopulation of VERIFY Study

Autor: Juan Manosalva, Chantal Mathieu, Sergio Vencio, Paivi M. Paldanius, Pieter Proot

Publikováno v: Diabetes. 69

The VERIFY study showed long-term clinical benefits of the early combination therapy of vildagliptin with metformin (EC) vs. traditional stepwise approach initiating with metformin monotherapy (MET) in a multinational population of newly diagnosed ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a32f52960088407d1a0a3d0a5e6b2db9
https://doi.org/10.2337/db20-94-lb

Clinical Diabetes/Therapeutics.

Publikováno v: Diabetes; Jun 2014 Supplement, pA595-A631, 37p, 18 Charts, 9 Graphs

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.

Autor: Strain WD; Diabetes and Vascular Medicine Research Centre, National Institute for Health Research Exeter Clinical Research Facility and Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK., Paldánius PM; Novartis Pharma AG, Basel, Switzerland.

Publikováno v: European endocrinology [Eur Endocrinol] 2017 Aug; Vol. 13 (2), pp. 62-67. Date of Electronic Publication: 2017 Aug 22.